Status:
COMPLETED
Aging and Frailty Study
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Effects of Chemotherapy
Aging
Eligibility:
All Genders
65+ years
Brief Summary
The purpose of this research study is to compare methods to help personalize the prediction of chemotherapy side effects for older adults and to evaluate whether chemotherapy causes changes in the bod...
Detailed Description
Primary Objective: Describe mean and variation of the electronic frailty index-cancer, geriatric measures, patient reported outcomes, and biomarkers of aging of chemotherapy, and their change.
Eligibility Criteria
Inclusion
- Age 65 years and older
- Planned to initiate a new chemotherapy regimen
- Solid tumor malignancy of any stage or lymphoma
- Any performance status
- Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
- Life expectancy of ≥3 months
Exclusion
- Initiating biologic, endocrine or immunotherapy only.
- Hematologic malignancy other than lymphoma.
- Concurrent radiation therapy.
- Planned inpatient chemotherapy.
Key Trial Info
Start Date :
May 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 13 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05268991
Start Date
May 2 2022
End Date
June 13 2025
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157